Industry Insights
Deep dives on clinical endpoints, regulatory trends and data quality — written and curated by the EClinCloud team.
The value of eCOA in the era of digitally derived measuresAs clinical research explores digitally derived measures, eCOA can connect patient experience with other digital measurements through fit-for-purpose assessments and sound data quality management.
FDA COA Evidence Dossier in 2026: A Planning Crosswalk and Draft-Status ReviewMap COA evidence to the September 2025 discussion draft, compare stakeholder requests and keep draft proposals separate from effective submission requirements.
Clinical Outcome Instruments: From Registry Names to CDISC QRS and Study-Build DecisionsWhat 299,607 registered studies reveal about instrument wording, CDISC QRS and NIH CDE discovery, with a study-build checklist.
eCOA Linguistic Validation 2026: Translate, Adapt, License or Revalidate for a Multinational Trial?A cell-based framework for licensing, translating, adapting or validating eCOA versions across languages, populations, modes and contexts of use.
FDA PFDD Guidance 3 and ClinicalTrials.gov 2026: PRO vs ClinRO Tokens, Patient-Reported Outcome Registration, and eCOA ImplementationFDA PFDD Guidance 3 is a fit-for-purpose selection file. ClinicalTrials.gov outcome text almost never stores COA type; PRO language is common and still not validation.
From regulatory intent to practice: choosing a fit-for-purpose clinical outcome assessmentA practical overview of FDA PFDD Guidance 3, the four COA types, fit-for-purpose evidence, and how eCOA supports patient-focused endpoint implementation.